(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...
Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...
Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...
Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Personalized Care A nurse practitioner with NYU's pulmonary intervention team chronicles the NSCLC patient experience from diagnosis to ...
CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by ...
A solitary pulmonary nodule (SPN) is an isolated lung growth surrounded by normal tissue. Most SPNs are benign (not cancerous) when they're diagnosed. However, some nodules can enlarge and change over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback